[Use of pentoxifylline in the treatment of systemic scleroderma].
Analyzes in the paper are chief pharmacological effects of pentoxifylline; the necessity is substantiated of its prescription in a combined therapy of systemic scleroderma (SSD). As many as 220 SSD patients on an in-patient care were examined. Apart from general clinical, biochemical, immunological methods of investigation, the condition of the microcirculation system was studied, the level of the tumor necrosis serumal factor alfa (TNF-alpha) was measured. The data secured suggest a considerable increase in the level of TNF-alpha and pronounced disturbances in microcirculation. The administration of pentoxifylline to SSD patients has been found to improve the microcirculation and reduce the production of the above factor, which fact suggests its immunomodulating properties.
Neĭko
Ie M
IeM
Iatsyshyn
R I
RI
D000328:Adult; D005260:Female; D006401:Hematologic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000187:drug effects
D006401:Hematologic Agents; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline
Zastosuvannia pentoksyfilinu v likuvanni systemnoï sklerodermiï.